Drug intelligence / Profile preview

TJ085

Development stage: Preclinical
Lead developer: Tuojie Biotech
Modality: Small Molecules
Administration: Oral

Overview

TJ085 is a small molecule inhibitor of the Werner syndrome ATP-dependent helicase (WRN), currently in the IND-enabling stage for the treatment of solid tumors. Developed by Tuojie Biotech, the compound is designed to exploit synthetic lethality in tumors characterized by microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR). By inhibiting the helicase activity of WRN, TJ085 induces catastrophic DNA damage and cell death specifically in MSI-H cancer cells, providing a targeted approach for patients with these specific genetic signatures.

Targets

WRN (Werner syndrome ATP-dependent helicase)

Beyond the preview

Go deeper on TJ085.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ085.

Explore the full profile